Challenges in drug discovery for novel antifilarials

Expert Opinion on Drug Discovery

Volumn 2, Issue SUPPL. 1, 2007, Pages

  Townson, Simon ^a   Ramirez, Bernadette ^b   Fakorede, Foluke ^b   Mouries, Marie Annick ^b   Nwaka, Solomon ^b  

^a NORTHWICK PARK INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antifilarial drug discovery; Compound screening; Helminth drug initiative; Lymphatic filariasis; Onchocerciasis

Indexed keywords

ALBENDAZOLE; AMOCARZINE; ANTIBIOTIC AGENT; ANTIFILARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; DIETHYLCARBAMAZINE; DOXYCYCLINE; HALOFANTRINE; IMMITICIDE; IVERMECTIN; MEFLOQUINE; MELARSAMINE; MOXIDECTIN; PRAZIQUANTEL; TETRAZOLIUM; UNCLASSIFIED DRUG;

ARTICLE; BLINDNESS; CELL CULTURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; FILARIASIS; HEALTH PROGRAM; HUMAN; HYDROCELE; IN VITRO STUDY; LOA LOA; LYMPHEDEMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCHOCERCA; ONCHOCERCA GUTTUROSA; ONCHOCERCA LIENALIS; ONCHOCERCIASIS; PARASITE CONTROL; PARASITE DEVELOPMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; WUCHERERIA BANCROFTI;

EID: 35448966646     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.S1.S63     Document Type: Article

References (101)

1. RICHARDS FO Jr, BOATIN B, SAUERBREY M, SEKETELI A: Control of onchocerciasis today: status and challenges. Trends Parasitol. (2001) 17(12):558-563.
2. MOLYNEUX DH, ZAGARIA N: Lymphatic filariasis elimination: progress in global programme development. Ann. Trop. Med. Parasitol. (2002) 96(Suppl. 2):S15-S40.
3. MOLYNEUX DH, BRADLEY M, HOERAUF A, KYELEM D, TAYLOR MJ: Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol. (2003) 19(11):516-522.
4. ABARU DE, MCMAHON JE: Metrifonate in onchocerciasis and lymphatic filariasis. Tropenmed Parasitol. (1978) 29(2):175-177.
5. MERLIN M, CARME B, KASUFFER H, LAIGRET J: Activity of levamisole (Solaskil) in lymphatic filariasis caused by Wuchereria bancrofti. (variety pacifica). Bull. Soc. Pathol. Exot. Filiales (1976) 69(3):257-265.
6. SUBRAHMANYAM D: Antifilarials and their mode of action. Ciba Found. Symp. (1987) 127:246-264.
7. ANDERSON J, FUGLSANG H, DE C MARSHALL TF: Effects of diethylcabamzine on ocular onchocerciasis. Tropenmed. Parasitol. (1976) 27(3):263-278.
8. ANDERSON J, FUGLSANG H, DE C MARSHALL TF: Effects of suramin on ocular onchocerciasis. Tropenmed Parasitol. (1976) 27(3):279-296.
9. JONES BR, ANDERSON J, FUGLSANG H: Evaluation of microfilaricidal effects in the cornea from topically applied drugs in ocular onchocerciasis: trials with levamisole and mebendazole: Br. J. Ophthalmol. (1978) 62(7):440-444.
10. AWADZI K, GILLES HM: The chemotherapy of onchocerciasis. iii. A comparative study of diethylcarbamazine (DEC) and metrifonate. Ann. Trop. Med. Parasitol. (1980) 74(2):199-210.
11. RIVAS-ALCALA AR, GREENE BM, TAYLOR HR et al.: Chemotherapy of onchocerciasis: a controlled comparison of mebendazole, levamisole, and diethylcarbamazine. Lancet (1981) 2(8245):485-490.
12. MAK JW: Antifilarial compounds in the treatment and control of lymphatic filariasis: Trop. Biomed. (2004) 21(2):27-38.
13. GYAPONG JO, KUMARASWAMI V, BISWAS G, OTTESEN EA: Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin. Pharmacother. (2005) 6(2):179-200.
14. BOATIN BA, RICHARDS FO: Control of onchocerciasis. Adv. Parasitol. (2006) 61:349-394.
15. THYLEFORS B, ALLEMAN M: Towards the elimination of onchocerciasis. Ann. Trop. Med. Parasitol. (2006) 100(8):733-746.
16. HOMEIDA M, BRAIDE E, ELHASSAN E et al.: APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African programme for onchocerciasis control. Ann. Trop. Med. Parasitol. (2002) 96(Suppl. 1):S93-S104.
17. BURKOT TR, TALEO G, TOEASO V, ICHIMORI K: Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities. Ann. Trop. Med. Parasitol. (2002) 96(Suppl. 2):S61-S69.
18. BOCKARIE MJ, TISCH DJ, KASTENS W et al.: Mass treatment to eliminate filariasis in Papua New Guinea. N. Engl. J. Med. (2002) 347(23):1841-1848
19. ADDISS D, CRITCHLEY J, EJERE H et al.: Albendazole for lymphatic filariasis. Cochrane Database Syst. Rev. (2004) 1:CD003753 (Review). Update in: Cochrane Database Syst. Rev. (2005) 4:CD003753.
20. CRITCHLEY J, ADDISS D, GAMBLE C, GARNER P, GELBAND H, EJERE H: INTERNATIONAL FILARIASIS REVIEW GROUP: Albendazole for lymphatic filariasis. Cochrane Database Syst. Rev. (2005) 4:CD003753.
21. HORTON J, WITT C, OTTESEN EA et al.: An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology (2000) 121(Suppl.):S147-S160.
22. ALLEMAN MM, TWUM-DANSO NA, THYLEFORS BI: The Mectizan donation program - highlights from (2005). Filaria J. (2006) 5:11.
23. OTTESEN EA, ISMAIL MM, HORTON J: The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol. Today (1999) 15(9):382-386.
24. MOLYNEUX DH: Onchocerciasis control in West Africa: current status and future of onchocerciasis control programmes. Parasitol. Today (1995) 11:399-402.
25. BENTON B, BUMP J, SEKETELI A, LIESE B: Partnership and promise: evolution of the African river-blindness campaigns. Ann. Trop. Med. Parasitol. (2002) 96(Suppl. 1):S5-S14.
26. OTTESEN EA, DUKE BO, KARAM M, BEHBEHANI K: Strategies and tools for the control/elimination of lymphatic filariasis. Bull. World Health Organ. (1997) 75(6):491-503.
27. MOLYNEUX DH, TAYLOR MJ: Current status and future prospects of the global lymphatic filariasis programme. Curr. Opin. Infect. Dis. (2001) 14(2):155-159.
28. TIELSH JM, BEECHE A: Impact of ivermectin on illness and disability associated with onchocerciasis. Trop. Med. Int. Health (2004) 9(4):A45-A56.
29. HOERAUF A: New strategies to combat filariasis. Expert Rev. Antiinfect. Ther. (2006) 4(2):211-222.
30. STEPHENSON LS: Optimising the benefits of anthelmintic treatment in children. Paediatr. Drugs (2001) 3(7):495-508.
31. ALLEY WS, VAN OORTMARSSEN GJ, BOATIN BA et al.: Macrofilaricides and onchocerciasis control, mathematical modelling of the prospects for elimination. BMC Public Health (2001) 1:12.
32. DE KRAKER MEA, STOLK WA, VAN OORTMARSSEN GJ, HABBEMA JD: Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti. Trop. Med. Int. Health (2006) 11(5):718-728.
33. GEERTS S, GRYSEELS B: Drug resistance in human helminths: current situation and lessons from livestock. Clin. Microbiol. Rev. (2000) 13(2):207-222.
34. KAPLAN RM: Anthelminthic resistance in nematodes of horses. Vet. Res. (2002) 33(5):491-507.
35. PRICHARD RK: Is anthelminthic resistance a concern for heartworm control? What can we learn from the human filariasis control programs? Vet. Parasitol. (2005) 133(2-3):243-253.
36. PRICHARD RK, VON SAMSON-HAMMELSTJERNA G, BLACKHALL WJ, GEARY TG: Foreword: towards markers for anthelminthic resistance in helminths of importance in animal and human health. Parasitology (2007) 134(Part 8):1073-1076.
37. OSEI-ATWENEBOANA MY, ENG JK, BOAKYE DA, GYAPONG JO, PRICHARD RK: Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet (2007) 369(9578):2021-2029.
38. PRICHARD RK: Ivermectin resistance and overview of the consortium for anthelminthic resistance SNPs. Expert Opin. Drug Discov. (2007) 2(Suppl. 1):xx-yy.
39. ACHUKWI MD, HARNETT W, ENYONG P, RENZ A: Successful vaccination against Onchocerca ochengi infectation in cattle using live Onchocerca volvulus infective larvae. Parasite Immunol. (2007) 29(3):113-116.
40. TAGBOTO S, TOWNSON S: Antiparasitic properties of medicinal plants and other naturally occurring products. Adv. Parasitol. (2001) 50:199-295.
41. TOWNSON S, HUTTON D, SIEMIENSKA J et al.: Antibiotics and Wolbachia in filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi. Ann. Trop. Med. Parasitol. (2000) 94(8):801-816.
42. HOERAUF A, MAND S, ADJEI O, FLEISCHER B, BÜTTNER DW: Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet (2001) 357(9266):1415-1416.
43. BABAYAN SA, ATTOUT T, HARRIS A et al.: Vaccination against filarial nematodes with irradiated larvae provides long-term protection against the third larval stage but not against subsequent life cycle stages. Int. J. Parasitol. (2006) 36(8):903-914.
44. RAMACHANDRAN S, KUMAR MP, RAMI RM et al.: The larval specific lymphatic filarial ALT-2: induction of protection using protein or DNA vaccination. Microbiol. Immunol. (2004) 48(12):945-955.
45. GNANASEKAR M, RAO KV, HE YX et al.: Novel phage display-based subtractive screening to identify vaccine candidates of Brugia malayi. Infect. Immun. (2004) 72(8):4707-4715.
46. NUTMAN TB: Future directions for vaccine-related onchocerciasis research. Trends Parasitol. (2002) 18(6):237-239.
47. LUSTIGMAN S, JAMES ER, TAWE W, ABRAHAM D: Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends Parasitol. (2002) 18(3):135-141.
48. ABRAHAM D, LEON O, LEON S, LUSTIGMAN S: Development of a recombinant antigen vaccine against infection with the filarial worm Onchocerca volvulus. Infect. Immun. (2001) 69(1):262-270.
49. LIZOTTE-WANIEWSKI M, TAWE W, GUILIANO DB et al.: Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of Onchocerca volvulus larval cDNA libraries. Infect. Immun. (2000) 68(6):3491-3501.
50. SHOOP W: Ivermectin and moxidectin are cross-resistant in nematodes and the rate of development is the same. Final report of the Conference on the eradicability of onchocerciasis. Filaria J. (2003) 2:2.
51. HOERAUF A, VOLKMANN L, HAMELMANN C et al.: Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet (2000) 355(9211):1242-1243.
52. TOWNSON S, TAGBOTO S, MCGARRY HF, EGERTON GL, TAYLOR MJ: Onthocerca parasites and Wolbachia endosymbionts: evaluation of a spectrum of antibiotic types for activity against Onchocerca gutturosa in vitro. Filaria J. (2006) 5:4.
53. PFARR KM, HOERAUF AM: Antibiotics which target the Wolbachia endosymbionts of filarial parasites: a new strategy for control of filariasis and amelioration of pathology. Mini Rev. Med. Chem. (2006) 6(2):203-210.
54. TAYLOR MJ, MAKUNDE WH, MCGARRY HF, TURNER JD, MAND S, HOERAUF A: Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet (2005) 365(9477):2067-2068.
55. TURNER JD, MAND S, DEBRAH AY et al.: A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin. Infect. Dis. (2006) 42(8):1090-1092.
56. MCKELLAR QA, JACKSON F: Veterinary anthelmintics: old and new. Trends Parasitol. (2004) (10):456-461.
57. WALLER PJ: From discovery to development: current industry perpectives for the development of novel methods of helminth control in livestock. Vet. Parasitol. (2006) 139(1-3):1-14.
58. FOX LM: Ivermectin: uses and impact 20 years on. Curr. Opin. Infect. Dis. (2006) 19(6)188-593.
59. GUTTERIDGE WE: TDR collaboration with the pharmaceutical industry. Trans. R. Soc. Trop. Med. Hyg. (2006) 100(Suppl. 1):S21-S25.
60. NWAKA S: Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines. Trans. R. Soc. Trop. Med. Hyg. (2005) 99(Suppl. 1):S20-S29.
61. CROFT SL: Public-private partnership: from there to here. Trans. R. Soc. Trop. Med. Hyg. (2005) 99(Suppl. 1):S9-S14.
62. WIDDUS R: Public-private partnerships: an overview. Trans. R. Soc. Trop. Med. Hyg. (2005) 99(Suppl. 1):S1-S8.
63. WHEELER C, BERKLEY S: Initial lessons from public-private partnerships in drug and vaccine development. Bull. World Health Organ. (2001) 79(8):728-734.
64. NWAKA S, HUDSON A: Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. (2006) 5(11):941-955.
65. TAYLOR AE: Maintenance of filarial worms in vitro. Exp. Parasitol. (1960) 113:20.
66. CHEN SN, HOWELLS RE: The in vitro cultivation of the infective larvae and the early mammalian stages of the filarial worm, Brugia pahangi. Ann. Trop. Med. Parasitol. (1979) 73(5):473-486.
67. CHAPPELL LH: World health organization onchocerciasis chemotherapy project: In vitro culture on filarial parasites, especially Onchocerca spp. Int. J. Parasitol. (1985) 15(5):475-476.
68. MAKI J: A review of the long term in vitro maintenance of adult filarial worms releasing microfilariae. Kirasato Arch. Exp. Med. (1991) 64(4):179-182.
69. TOWNSON S, SHAY KE, DOBINSON AR, CONNELLY C, COMLEY JC, ZEA-FLORES G: Onchocerca gutturosa and O. volvulus: studies on the viability and drug responses of cryopreserved adult worms in vitro. Trans. R. Soc. Trop. Med. Hyg. (1989) 83(5):664-669.
70. TOWNSON S, DOBINSON AR, TOWNSEND J, SIEMIENSKA J, ZEA-FLORES G: The effects of ivermectin used in combination with other known antiparasitic drugs on adult Onchocerca gutturosa and O. volvulus in vitro. Trans. R. Soc. Trop. Med. Hyg. (1990) 84(3):411-416.
71. FRANKE ED, RIBERU W, WIADY I: Evaluation of medium supplements for in vitro cultivation of Wuchereria bancrofti. J. Parasitol. (1990) 76(2):262-265.
72. FALCONE FH, ZAHNER H, SCHLAAK M, HAAS H: In vitro cultivation of third-stage larvae of Brugia malayi to the young adult stage. Trop. Med. Parasitol. (1995) 46(4):230-234.
73. TOWNSON S, TAGBOTO SK: In vitro cultivation and development of Onchocerca volvulus and Onchocerca lienalis microfilariae. Am. J. Trop. Med. Hyg. (1996) 54(1):32-37.
74. STROTE G, BONOW I, KROMER M, RUBIO DE KROMER T, ATTAH S, OPOKU N: Chemotherapy for onchocerciasis: results of in vitro experiments with promising new compounds. Trop. Med. Int. Health. (1998) 3(5):397-407.
75. SMITH HL, PACIORKOWSKI N, BABU S, RAJAN TV: Development of a serum-free system for the in vitro cultivation of Brugia malayi infective-stage larvae. Exp. Parasitol. (2000) 95(4):253-264.
76. GUNAWARDENA NK, FUJIMAKI Y, AOKI Y et al.: Differential effects of diethylcarbamazine, tetracycline and the combination on Brugia pahangi adult females in vitro. Parasitol Int. (2005) 54(4):253-259.
77. FUJIMAKI Y, KAMACHI T, YANAGI T, CACERES A, MAKI J, AOKI Y: Macrofilaricidal and microfilaricidal effects of Neurolaena lobata, a Guatemalan medicinal plant, on Brugia pahangi. J. Helminthol. (2005) 79(1):23-28.
78. MISHRA V, KHAN NU, SINGHAL KC: Potential antifilarial activity of fruit extracts of Ficus racemosa Linn. against Setaria cervi in vitro. Indian J. Exp. Biol. (2005) 43(4):346-350.
79. HAM PJ, TOWNSON S, JAMES EF, BIANCO AE: An improved technique for cryopreservation of Onchocerca microfilariae. Parasitology (1981) 83(Part 1):139-146.
80. COURT JP, BIANCO AE, TOWNSON S, HAM PJ, FIEDHEIM E: Study on the activity of antiparasitic agents against Onchocerca lienalis third stage larvae in vitro. Trop. Med. Parasitol. (1985) 36(2):117-119.
81. TOWNSON S, CONNELLY C, MULLER R: Optimization of culture conditions for the maintenance of Onchocerca gutturosa adult worms in vitro. J. Helminthol. (1986) 60(4):323-330.
82. TOWNSON S, CONNELLY C, DOBINSON A, MULLER R: Drug activity against Onchocerca gutturosa males in vitro: a model for chemotherapeutic research on onchocerciasis. J. Helminthol. (1987) 61(4):271-281.
83. COMLEY JC, TOWNSON S, REES MJ, DOBINSON A: The further application of MTT-formazan colorimetry to studies on filarial worm viability. Trop. Med. Parasitol. (1989) 40(3):311-316.
84. TOWNSON S, BIANCO AE: Experimental infection of mice with the microfilariae of Onchocerca lienalis. Parasitology (1982) 85(Part 2):283-293.
85. BIANCO AE, NWACHUKWU MA, TOWNSON S: DOENHOFF MJ, MULLER RL: Evaluation of drugs against Onchocerca microfilariae in an inbred mouse model. Trop. Med. Parasitol. (1986) 37(1):39-45.
86. TOWNSON S, DOBINSON A, CONNELLY C, MULLER R: Chemotherapy of Onchocerca lienalis microfilariae in mice: a model for the evaluation of novel compounds for the treatment of onchocerchiasis. J. Helminthol. (1988) 62(3):181-194.
87. EWERT A, FOLSE D: Animal model of human disease. Lymphatic filariasis. Am. J. Pathol. (1984) 115(1):135-137.
88. DEVANEY E, HOWELLS RE, SMITH G: Brugia pahangi in the BALB/c mouse: a model for testing filaricidal compounds. J. Helminthol. (1985) 59(2):95-99.
89. DENHAM DA, FLETCHER C: The car infected with Brugia pahangi as a model of human filariasis. Ciba Found. Symp. (1987) 127:225-235.
90. CAMPBELL JR, MARWOTO HA, TIRTOKUSUMO S et al.: The silvered leaf monkey (Presbytis cristata) as a model for human bancroftian filariasis. Lab. Anim. Sci. (1987) 37(4):502-504.
91. SNOWDEN KF, HAMMERBERG B: The lymphatic pathology of chronic Brugia pahangi infection in the dog. Trans. R. Soc. Trop. Med. Hyg. (1989) 83(5):670-678.
92. MAEDA R, HAYASHI Y, SHIBUYA T: Basic studies on the laboratory assessment of macrofilaricides using Brugia malayi in the jird, Meriones unguiculatus. 2. Establishment and evaluation of a new method of macrofilaricide assessment. Jpn. J. Exp. Med. (1988) 58(1):45-49.
93. LOK JB, ABRAHAM D: Animal models for the study of immunity in human filariasis. Parasitol. Today (1992) 8(5):168-171.
94. BEERNTSEN BT, LOWENBERGER CA, KLINKHAMMER JA, CHRISTENSEN LA, CHRISTENSEN BM: Influence of anesthetics on the peripheral blood microfilaremia of Brugia malayi in the Mongolian jird, Meriones unguiculatus. J. Parasitol. (1996) 82(2):327-330.
95. LAKSHMI V, SAXENA A, PANDEY K, BAJPAI P, MISRA-BHATTACHARYA S: Antifilarial activity of Zoanthus species (Phylum Coelenterata, Class Anthozoa) against human lymphatic filarial, Brugia malayi. Parasitol. Res. (2004) 93(4):268-273.
96. DUKE BO: A plea to continue the search for an Onchocerca volvulus macrofilaricide. Trans. R. Soc. Trop. Med. Hyg. (2002) 96:575-576.
97. MELROSE WD: Chemotherapy for lymphatic filariasis: progress but not perfection. Expert Rev. Anti. Infect. Ther. (2003) 1(4):571-577.
98. BEHM CA, BENDIG MM, MCCARTER JP, SLUDER AE: RNAi-based discovery and validation of new drug targets in filarial nematodes. Trends Parasitol. (2005) 21(3):97-100.
99. TAGBOTO SK, TOWNSON S: Onchocerca volvulus and O. lienalis. the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo. Ann. Trop. Med. Parasitol. (1996) 90(5):497-505.
100. COURT JP, STABLES JN, LEES GM, MARTIN-SHORT MR, RANKIN R: Dipetalonema viteae and Brugia pahangi transplant infections in gerbils for use in antifilarial screening. J. Helminthol. (1988) 62(1):1-9.
101. TOWNSON S, TAGBOTO SK, CASTRO J, LUJAN A, AWADZI K, TITANJI VP: Comparison of the sensitivity of different geographical races of Onchocerca volvulus microfilariae to ivermectin: studies in vitro. Trans. R. Soc. Trop. Med. Hyg. (1994) 88(1)101-106.